About Maze Therapeutics
Maze Therapeutics is a company based in Redwood City (United States) founded in 2018. Maze Therapeutics has raised $496 million across 5 funding rounds from investors including Janus Henderson Investors, Piper Sandler and Driehaus. The company has 125 employees as of December 31, 2024. Maze Therapeutics operates in a competitive market with competitors including Metabolon, Alector, Seer, Tango Therapeutics and NeoPhore, among others.
- Headquarter Redwood City, United States
- Employees 125 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Maze Therapeutics, Inc.
-
Annual Revenue
$167.5 M (USD)0as on Dec 31, 2024
-
Net Profit
$18.38 M (USD)0as on Dec 31, 2024
-
EBITDA
$60.88 M (USD)0as on Dec 31, 2024
-
Total Equity Funding
$496 M (USD)
in 5 rounds
-
Latest Funding Round
$150 M (USD), Post-IPO
Sep 11, 2025
-
Investors
Janus Henderson Investors
& 22 more
-
Employee Count
125
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Maze Therapeutics
Maze Therapeutics is a publicly listed company on the NASDAQ with ticker symbol MAZE in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Maze Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Maze Therapeutics
Maze Therapeutics has successfully raised a total of $496M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $150 million completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Maze Therapeutics
Maze Therapeutics has secured backing from 23 investors, including venture fund and institutional investors. Prominent investors backing the company include Janus Henderson Investors, Piper Sandler and Driehaus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Deep Track Capital is engaged in biotechnology investment activities.
|
Locked | Locked | Locked | |
|
Healthcare investment firm focused on novel therapeutics development.
|
Locked | Locked | Locked | |
|
Private equity fund focused on the biotechnology sector
|
Locked | Locked | Locked |
Investor details for Maze Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Maze Therapeutics
Investment portfolio details for Maze Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Maze Therapeutics
Detailed financials for Maze Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Maze Therapeutics Comparisons
Peer comparison for Maze Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Maze Therapeutics
Maze Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Metabolon, Alector, Seer, Tango Therapeutics and NeoPhore, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Solutions for biomarker discovery and diagnostic testing are provided.
|
|
| Locked | Locked | Locked |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
|
|
| Locked | Locked | Locked |
Proteomics platform developed for early cancer and neurological disease detection.
|
|
| Locked | Locked | Locked |
Novel cancer drugs are developed using synthetic lethality screening.
|
|
| Locked | Locked | Locked |
NeoPhore is focused on cancer neoantigen evolution therapies.
|
Detailed competitors of Maze Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Maze Therapeutics
Complete news archive for Maze Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Maze Therapeutics
Maze Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Maze Therapeutics is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
Jason Coloma is the current CEO of Maze Therapeutics.
Maze Therapeutics is a funded company, having raised a total of $496M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Maze Therapeutics is 125.
Annual revenue of Maze Therapeutics is $167.5M as on Dec 31, 2024.
Maze Therapeutics was founded in 2018 and is headquartered in Redwood City, United States. Genetic biomarkers and integrated technologies are developed to identify modifiers in neurological, metabolic, and renal diseases. Operations extend to oncology, with a focus on therapeutic applications in the biotechnology sector. Research efforts target disease mechanisms through genetic analysis.
Maze Therapeutics's top competitors include Alector, Lexicon Pharmaceuticals and Metabolon.
Yes, Maze Therapeutics is publicly traded on NASDAQ under the ticker symbol MAZE.
Maze Therapeutics has 23 investors. Key investors include Janus Henderson Investors, Piper Sandler, Driehaus, Arch Venture Partners, and Deep Track Capital.
The ticker symbol of Maze Therapeutics is MAZE on NASDAQ.